ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0922

Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib

Nuria Barbarroja1, Carlos Pérez-Sánchez1, Laura Cuesta-Lopez1, Miriam Ruiz-Ponce1, Ivan Arias-de la Rosa1, Antonio Gonzalez2, Eva Perez Pampin3, Chamaida Plasencia-Rodriguez4, Ana Martinez-Feito4, Rafaela Ortega-Castro1, Jerusalem Calvo-Gutierrez5, Alejandro Balsa6, Alejandro Escudero-Contreras1, Eduardo Collantes1 and Chary López-Pedrera7, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, 3Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, 4Rheumatology Department, La Paz University Hospital, Madrid, Spain, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 6Hospital La Paz Institute for Health Research, Madrid, Spain, 7Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Comorbidity, rheumatoid arthritis, Therapy, complementary

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients may provide disease biomarkers and insights into the biological pathways that contribute to the cardiovascular risk.

Objectives: 1) To evaluate the changes in the cardiometabolic and cardiovascular serum proteome in two cohorts of active RA patients: new diagnosed (naïve-treated) and well-established disease and its association with the clinical characteristics and 2) to analyze the modulation of the levels of these proteins by methotrexate and tofacitinib.

Methods: 1) Cross-sectional study in two cohorts of RA: patients at diagnosis (evolution time <2 years, n=25) and patients with established disease (evolution time>25 years, n=25), age and sex-matched with healthy donors (n=25). 2) Longitudinal study was performed on 25 RA patients treated with methotrexate and 25 RA patients treated with Tofacitinib combined with DMARDs for 6 months. Clinical and analytical variables were recorded. Proteomic profiling of 184 proteins (cardiometabolic and cardiovascular II panels) was performed in the serum using Olink Proteomics technology.

Results: There were no statistical differences between the RA at diagnosis and RA established disease groups in age and DAS28. The evolution time mean in the RA established disease group was 37.48 ±11.79 years. One hundred and seven proteins were significantly increased in the serum of RA patients at diagnosis versus healthy donors, among these 47 proteins were elevated in RA patients with established disease. The PCA analysis showed that the alteration of these proteins could discriminate between RA patients and healthy donors. The molecules more significantly increased in the RA at diagnosis group were SAA4, ST6GAL1, CCL18, TNC, IGLC2, IL6, SORT1, TNFRSF10A, AGRP, and CD4. In addition, the top ten molecules significantly elevated in RA patients with established disease were SAA4, CCL18, ST6GAL1, CRTAC1, ANGPTL3, TNFRSF10A, LEP, Gal-9, SORT1, and TRAIL-R2. The increase of these proteins was associated with the inflammation shown by the correlation with C reactive protein (CRP) levels and DAS28. The elevated levels of SAA4 (serum amyloid A protein-4) discriminated between RA patients and healthy donors with high sensitivity and specificity (AUC=0.95).

Treatment with methotrexate in RA patients at diagnosis reduced the levels of 64 proteins (50% of the altered proteins) while tofacitinib modulated the expression of 30 proteins (50% of the altered proteins) in RA patients with established disease after 6 months. These reductions were associated with the decrease in CRP and DAS28 levels.>

Conclusion: 1) The cardiovascular and cardiometabolic serum proteome is altered in RA patients at diagnosis and after a long time of the disease evolution and chronic treatments, 2) SAA4 may represent a biomarker for the diagnosis of RA with a high sensitivity and specificity, 3) Methotrexate and tofacitinib specifically modulate the alteration on the serum proteome after six months of treatment alongside the reduction of clinical inflammatory and disease activity markers.

Funded by Pfizer-IRS-Aspire 2019.


Disclosures: N. Barbarroja, None; C. Pérez-Sánchez, None; L. Cuesta-Lopez, None; M. Ruiz-Ponce, None; I. Arias-de la Rosa, None; A. Gonzalez, None; E. Perez Pampin, None; C. Plasencia-Rodriguez, None; A. Martinez-Feito, None; R. Ortega-Castro, None; J. Calvo-Gutierrez, None; A. Balsa, Bristol-Myers Squibb(BMS), Gebro-Pharma, Novartis, Roche, UCB, Pfizer, AbbVie/Abbott, Galapagos, Gilead, Sandoz, Lilly, Nordic; A. Escudero-Contreras, None; E. Collantes, None; C. López-Pedrera, None.

To cite this abstract in AMA style:

Barbarroja N, Pérez-Sánchez C, Cuesta-Lopez L, Ruiz-Ponce M, Arias-de la Rosa I, Gonzalez A, Perez Pampin E, Plasencia-Rodriguez C, Martinez-Feito A, Ortega-Castro R, Calvo-Gutierrez J, Balsa A, Escudero-Contreras A, Collantes E, López-Pedrera C. Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/alteration-of-the-cardiometabolic-and-cardiovascular-proteome-in-rheumatoid-arthritis-modulation-by-methotrexate-and-tofacitinib/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alteration-of-the-cardiometabolic-and-cardiovascular-proteome-in-rheumatoid-arthritis-modulation-by-methotrexate-and-tofacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology